Dr. Spiess on key penile and testis cancer research from AUA 2022

“Our data showed a considerable gap in reporting patient-reported outcomes and in the quality of design and conduct of patient-reported outcomes-related trial endpoints," said Jad Chahoud, MD, MPH.

Roger Li, MD, Moffit Cancer Center, was awarded the grant to study the novel oncolytic virus drug CG0070 in patients with intermediate-risk non–muscle-invasive bladder cancer.

FACT-RNT is the first tool to measure patient reported outcomes associated with radionuclide therapy for prostate cancer.

"Patients with intermediate-risk NMIBC remain an incredibly heterogeneous group," says Wei Shen Tan, MD, PhD.

OS was also found to be prolonged in the propensity score matched analysis, with a median that was not reached in the pembrolizumab arm vs 21 months in the IRC arm.

Moffitt Cancer Center conducted the first prospective study to investigate genomic biomarkers associated with aggressive disease in African American men with prostate cancer